NCT05386888CompletedPhase 2
A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC
A Phase 2 Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy for Patients With Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC)
Source: ClinicalTrials.gov · Last updated 2 Oct 2025
Brief summary (registry, in English)
This is a phase II trial assessing the efficacy and safety of GFH018 and Toripalimab in combination with concurrent chemoradiotherapy (cCRT) in patients with unresectable, locally advanced, Stage III non-small cell lung cancer (NSCLC).
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 65 (actual)
- First submitted
- 12 May 2022
- Start date
- 9 Sept 2022
- Primary completion date
- 31 Dec 2023
- Lead sponsor
- Genfleet Therapeutics (Shanghai) Inc.
- Diseases
- Lung cancer
- NCT number
- NCT05386888
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 65
- From 9 Sept 2022 to the primary completion date, 31 Dec 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Has received prior treatment (chemotherapy, targeted therapy, or radiotherapy) for Stage III NSCLC
- Prior exposure to immune-mediated therapy, including but not limited to, TGFβ inhibitors, anti CTLA-4, anti-PD-1, anti-PD-L1, and anti PD L2 antibodies.
- Patients whose radiation treatment plans are likely to encompass a volume of whole lung receiving ≥20 Gy in total (V20) of more than 35% of lung volume.
Other illness
- Has small cell lung cancer (SCLC) or tumors with the presence of small cell elements.
- Known allergy or hypersensitivity to any of the IPs or any of the IP excipients.
Who the study is looking for
- Age ≥ 18 years
- Newly diagnosed, pathologically (histologically or cytologically) confirmed, locally advanced, unresectable stage III NSCLC
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
- Measurable disease (according to RECIST v1.1 criteria)
- Life expectancy \> 6 months
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| West China Hospital，Sichuan University Coordinator of this site? Confirm its status | Chengdu | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.